From the Department of Internal Medicine (Aljohani, Alsalman, Ozair), King Abdulaziz Medical City Ministry of National Guard - Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences; from the Department of Nuclear Medicine (Saib, Syed), King Abdulaziz Medical City Ministry of National Guard - Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences; from the Division of Adult Hematology, Department of Oncology (Alhejazi, Alaskar, Gmati), King Abdulaziz Medical City Ministry of National Guard - Health Affairs, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences; from the Department of Biostatistics (Vishwakarm), King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences; and from the Clinical Trial Services (Mendoza), King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.
Saudi Med J. 2022 Aug;43(8):959-964. doi: 10.15537/smj.2022.43.8.20220055.
To find any correlation between the clinical response as per International Working Myeloma Group (IWMG) response criteria and the radiological response at the end of treatment.
A retrospective cohort study was conducted, total of 39 patients whom diagnosed with multiple myeloma (MM) between January 2010 and December 2018 and fulfilled the study criteria were included.
The high sensitivity and specificity of positron emission tomography/computed tomography (PET/CT) in detecting osteolytic myeloma lesions in the bones was strongly emphasized in our study. Follow up PET/CT, we found that while 17 patients showed complete remission in PET/CT, and 14 of these of patients demonstrated a complete clinical response at end of therapy assessment.
Although we did not find a statistically significant correlation between the response versus metabolic activity and the number of bone/bone marrow lesions, however, our study was limited by the absence of clear criteria for defining disease response in PET/CT in MM patients. Further prospective analysis would be needed to establish a defined criterion.
根据国际骨髓瘤工作组（IWMG）的反应标准，寻找临床反应与治疗结束时的放射学反应之间的任何相关性。
进行了一项回顾性队列研究，共纳入 39 名 2010 年 1 月至 2018 年 12 月期间诊断为多发性骨髓瘤（MM）且符合研究标准的患者。
我们的研究强烈强调了正电子发射断层扫描/计算机断层扫描（PET/CT）在检测骨骼溶骨性骨髓瘤病变方面的高灵敏度和特异性。进行了随访 PET/CT 检查，我们发现，虽然有 17 名患者在 PET/CT 中显示完全缓解，但其中 14 名患者在治疗结束时评估时表现出完全的临床缓解。
尽管我们没有发现反应与代谢活性和骨/骨髓病变数量之间存在统计学上的显著相关性，但我们的研究受到 MM 患者中 PET/CT 中定义疾病反应的明确标准缺失的限制。需要进一步的前瞻性分析来建立明确的标准。
